2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Unknown
1
Terminated
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Conditions
Breast Neoplasms
228
Neoplasm Metastasis
19
Neoplasms
9
Breast Neoplasms, Male
7
Breast Diseases
7
Ovarian Neoplasms
4
Carcinoma, Intraductal, Noninfiltrating
4
Recurrence
3
Obesity
3
Endometrial Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Breast Carcinoma In Situ
3
Breast Cancer Metastatic
3
Advanced Breast Cancer
3
Prostatic Neoplasms
2
Neoplasms by Site
2
Multiple Endocrine Neoplasia Type 1
2
Carcinoma, Renal Cell
2
Bulbo-Spinal Atrophy, X-Linked
2
Arthralgia
2
Vitamin D Deficiency
1
Uterine Cervical Neoplasms
1
Unilateral Breast Neoplasms
1
Tuberous Sclerosis
1
Triple Negative Breast Neoplasms
1
Thoracic Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sleep Wake Disorders
1
Skin Diseases
1
Sexuality
1
Interventions
bicalutamide
5
enzalutamide
4
exemestane
2
darolutamide
2
abiraterone
2
pembrolizumab
1
ostarine
1
nilutamide
1
cabazitaxel
1
apalutamide
1
abemaciclib
1
Vorinostat
1
Triptorelin Pamoate
1
Tamoxifen
1
Prophylactic Mastectomy
1
Prednisolone
1
Panobinostat
1
Mifepristone
1
Letrozole
1
Histamine H2 Antagonists
1
Histamine Antagonists
1
Goserelin
1
Doxorubicin
1
Docetaxel
1
Dasatinib
1
Cisplatin
1
CP protocol
1
Aromatase Inhibitors
1
Antiemetics
1
Anastrozole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Bulbo-Spinal Atrophy, X-Linked
×
exemestane
×
Clear all
NCT04869943
2024-01-26
ARTEST
Veru Inc.
Phase 3
Terminated
52 enrolled
NCT02910050
2017-12-22
BETTER
Sun Yat-sen University
Phase 2
Unknown
58 enrolled